Immune response following COVID-19 vaccination in children with cancer

Phase 4

Completed

• Conditions: <tr><td>Childhood cancer, Corona vaccination, immune response</td></tr>; Childhood cancer, Corona vaccination, immune response; 10047438

• Registration Number: NL-OMON21465
• Lead Sponsor: Princess Máxima Center for Pediatric Oncology

Brief Summary

Will follow

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 130

Inclusion Criteria

|
- Bereid gevaccineerd te worden met een routine Pfizer of Moderna vaccin, als onderdeel van het nationalevaccinatieprogramma (cohort I) |

Exclusion Criteria

|
- Voorgeschiedenis van ernstige ongewenste reacties, geassocieerd met een vaccin en/of ernstige allergischereactie (bijv. anafylactisch) op een grondstof van het vaccin |

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br><tr><br><td>The primary study parameter is the antibody based immune response to vaccination against COVID-19 28 days (t=3) after the second vaccination as compared to a control cohort.</td><br></tr><br><br>

Secondary Outcome Measures

Name	Time	Method
<br><tr><br><td>-Titers of SARS-CoV-2 specific antibodies at 12 months after the second vaccination<br /><br>-SARS-CoV2 specific T cell response measured at baseline, 21-28 days after first vaccination and at 28 days after the second vaccination</td><br></tr><br>